[sheet: Tracker Overview]
Field | Detail
Document Title | Interim Operating Covenant Compliance Tracker
Matter Number | 1018-00008
Client | Penterra Pharmaceuticals Corp. (Nasdaq: PPCA)
Target | Veridian Biosciences, Inc.
Transaction | Stock Purchase Agreement — $900,000,000 Acquisition of 100% of Outstanding Capital Stock of Veridian
SPA Execution Date | June 10, 2024
SPA Outside Date | December 10, 2024
Governing SPA Provision | Section 5.1 (Conduct of Business; Interim Operating Covenants)
Related SPA Provisions | § 5.1(a) (Ordinary Course); § 5.1(b) (Notification Obligations); § 5.4 (No-Shop)
Buyer's Counsel | Calderwood & Harkness LLP, 200 Park Avenue, 42nd Floor, New York, NY 10166
Responsible Partner | Oliver Mackenzie
Lead Associate | Megan Chu
Working Associate | Derek Okonkwo
Tax Associate | Lydia Cross
Seller's Counsel | Zalcourt Archer & Cole LLP — Rebecca Whitmore / Jonathan Pratt
Tracker Initiated | June 11, 2024
Last Updated | September 30, 2024
Status | TERMINATED — SPA terminated by Penterra on September 30, 2024 pursuant to § 8.1(d)
Confidentiality | PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT
[sheet: Covenant Compliance Log]
Item # | SPA Section | Covenant Description | Covenant Type | Consent Required from Penterra? | Monitoring Period Start | Monitoring Period End | Compliance Status | Date(s) of Relevant Activity | Description of Activity / Event | Consent Requested? | Consent Granted? | C&H Reviewer | Notes / Comments | Last Reviewed
1 | § 5.1(a) | Operate business in ordinary course consistent with past practice | Affirmative | No | 2024-06-10 | 2024-09-30 | Compliant (with exception — see Item 15) | General ordinary course operations | N/A | N/A | D. Okonkwo | No deviations identified through August 2024; protocol amendment flagged — see Item 15 | 2024-09-25
2 | § 5.1(a)(i) | Use commercially reasonable efforts to preserve intact business organization and goodwill | Affirmative | No | 2024-06-10 | 2024-09-30 | Under Review | 2024-08-14 | DMC recommendation to suspend enrollment in Marlowe Asset Management-2 trial may impact business organization preservation | N/A | N/A | M. Chu | Clinical hold and enrollment suspension raise questions about preservation of business as going concern; analysis ongoing as of termination | 2024-09-25
3 | § 5.1(a)(ii) | Use commercially reasonable efforts to keep available services of key employees | Affirmative | No | 2024-06-10 | 2024-09-30 | Compliant | No departures of key personnel (Dr. Marek, Dr. Chandrasekaran, S. Kessler, Dr. Fontaine) reported | N/A | N/A | D. Okonkwo | 148 employees at signing; no material departures reported through Sept. 30, 2024 | 2024-09-25
4 | § 5.1(a)(iii) | Maintain existing relationships with customers, suppliers, licensors, and other material business relationships | Affirmative | No | 2024-06-10 | 2024-09-30 | Under Review | 2024-08-22 | FDA partial clinical hold on VRD-4187 (IND 154832) may affect relationships with clinical sites (42 sites across US and EU) and CRO partners | N/A | N/A | M. Chu | Impact of clinical hold on trial site relationships being assessed | 2024-09-25
5 | § 5.1(b)(i) | No amendments to certificate of incorporation or bylaws | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No amendments reported | N/A | N/A | D. Okonkwo | Confirmed via periodic inquiries to LAC (Jonathan Pratt) | 2024-09-25
6 | § 5.1(b)(ii) | No issuance, sale, or grant of equity securities or options | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No equity issuances reported; ESOP pool (9.8%) unchanged | N/A | N/A | D. Okonkwo | Confirmed through periodic certifications | 2024-09-25
7 | § 5.1(b)(iii) | No declaration or payment of dividends or distributions | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No dividends or distributions declared or paid | N/A | N/A | D. Okonkwo | Clinical-stage company with $0 revenue; no distributions expected | 2024-09-25
8 | § 5.1(b)(iv) | No incurrence of indebtedness or guarantees | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No new indebtedness incurred | N/A | N/A | D. Okonkwo | Veridian cash position (~$112.4M as of March 31, 2024) sufficient for operations | 2024-09-25
9 | § 5.1(b)(v) | No acquisition or disposition of material assets outside ordinary course | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No material asset acquisitions or dispositions reported | N/A | N/A | D. Okonkwo | 2024-09-25
10 | § 5.1(b)(vi) | No entry into, amendment, or termination of material contracts | Negative | Yes | 2024-06-10 | 2024-09-30 | Under Review | 2024-08-28 | Veridian implemented Protocol v4.0 amendment (mandatory tocilizumab prophylaxis; dose reduction from 1.5 mg/kg to 0.75 mg/kg) — potential amendment of CRO agreement and clinical trial protocol | Partial — see Item 15 | Pending | M. Chu | C&H sent consent request letter to LAC (Rebecca Whitmore) on Aug. 30, 2024 inquiring whether Penterra consent was required; no definitive response received before termination | 2024-09-30
11 | § 5.1(b)(vii) | No changes in accounting methods or practices except as required by GAAP | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No changes to accounting methods reported; Northbridge Accounting Group LLP (Patrick Calloway) remains engaged as auditor | N/A | N/A | D. Okonkwo | 2024-09-25
12 | § 5.1(b)(viii) | No settlement of material litigation or claims | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No settlements reported | N/A | N/A | D. Okonkwo | 2024-09-25
13 | § 5.1(b)(ix) | No changes to compensation or benefits of employees except in ordinary course | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No material changes to compensation reported | N/A | N/A | D. Okonkwo | Key employee agreements (Marek, Chandrasekaran) reviewed at signing; no amendments reported | 2024-09-25
14 | § 5.1(b)(x) | No material changes to tax elections, filings, or settlements | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No changes to tax elections reported; Veridian EIN 84-2193047 | N/A | N/A | L. Cross | NOL carryforward ($312M as of Dec. 31, 2023) and §382 limitations (~$5.9M/yr on ~$148M pre-change NOLs) unchanged; state nexus in MA, CA, MD | 2024-09-25
15 | § 5.1(b)(xi) / § 5.1(a) | No material modification to clinical trial protocols without Buyer's consent | Negative | Yes | 2024-06-10 | 2024-09-30 | NON-COMPLIANT / DISPUTED | 2024-08-28 | Veridian implemented Protocol v4.0 amendment for VRD-4187 (Marlowe Asset Management-2 trial, NCT05837291): mandatory tocilizumab prophylaxis and dose reduction from 1.5 mg/kg to 0.75 mg/kg, without obtaining Penterra's prior written consent | No — Veridian acted unilaterally | N/A — consent not sought | M. Chu / O. Mackenzie | C&H sent consent request letter to LAC on Aug. 30, 2024 raising issue of whether consent was required. Veridian's position (per LAC Sept. 13 response) is that protocol amendment was required by DMC recommendation and FDA clinical hold and constituted ordinary course regulatory compliance. Penterra's position is that material clinical protocol modification required Buyer consent. Issue unresolved at termination. | 2024-09-30
16 | § 5.1(b)(xii) | No entry into agreements that would restrict or limit the Company's ability to compete post-closing | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No restrictive agreements entered | N/A | N/A | D. Okonkwo | 2024-09-25
17 | § 5.1(b)(xiii) | No creation or incurrence of liens on material assets except Permitted Liens | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No new liens reported; existing Permitted Liens per SPA Schedule 3.18 unchanged | N/A | N/A | D. Okonkwo | 2024-09-25
18 | § 5.1(b)(xiv) | No waiver, release, or assignment of material rights or claims | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No waivers or releases reported | N/A | N/A | D. Okonkwo | 2024-09-25
19 | § 5.1(b)(xv) | No capital expenditures in excess of $500,000 individually or $1,500,000 in aggregate without Buyer's consent | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No capital expenditures exceeding thresholds reported; routine lab equipment purchases within ordinary course | N/A | N/A | D. Okonkwo | Aggregate capex for interim period estimated at ~$380,000 per Veridian periodic certification | 2024-09-25
20 | § 5.1(b)(xvi) | No licensing or sublicensing of material intellectual property other than in ordinary course | Negative | Yes | 2024-06-10 | 2024-09-30 | Compliant | No new IP licenses or sublicenses reported; existing Solara Therapeutics co-exclusive license (VRD-4187 HER2+ indications) unchanged | N/A | N/A | D. Okonkwo | IP portfolio (12 issued patents, 7 pending applications per SPA Schedule 3.10) confirmed unchanged | 2024-09-25
21 | § 5.4 | No-Shop — no solicitation of or engagement with competing Acquisition Proposals | Negative | N/A | 2024-06-10 | 2024-09-30 | Compliant | No Acquisition Proposals received or solicited; no discussions with third parties | N/A | N/A | D. Okonkwo | Includes fiduciary-out for unsolicited Superior Proposals with 4 business days' matching rights for Penterra. No triggers reported. | 2024-09-30
SUMMARY
Total Covenants Tracked | 21
Compliant | 16
Non-Compliant / Disputed | 1
Under Review | 4
N/A | 0
[sheet: Notification Obligations Log]
Notification # | SPA Section | Notification Obligation | Event Triggering Notification | Date Event Occurred | Date Notification Required By | Date Notification Received by Penterra | Timely? | Notification Delivered By | Notification Received By | Content of Notification — Summary | Completeness Assessment | C&H Reviewer | Notes / Follow-Up | Last Reviewed
1 | § 5.1(b) | Prompt notice of any event, change, or development that would reasonably be expected to result in a material adverse effect or failure of any closing condition | Marlowe Asset Management-2 DMC interim analysis — DMC recommended suspension of enrollment and dose modification based on safety data (Grade ≥3 CRS: 23.4% treatment vs. 4.1% control; 7 treatment-related deaths vs. 1 in control; ORR: 31.4% vs. 28.9%, p=0.58) | 2024-08-14 | Prompt (interpreted as within 1–2 business days of event) | 2024-08-16 | Yes — received within 2 calendar days | Veridian (Dr. Julian Marek / Rachel Stein-Goldberg) via LAC (Rebecca Whitmore) | Penterra (Thomas F. Holbrook / Natalie Reiner); copy to C&H (Oliver Mackenzie / Megan Chu) | Summary of DMC interim analysis findings for Marlowe Asset Management-2 trial (387 enrolled patients across 42 sites); DMC recommendation to suspend enrollment and implement dose modification; preliminary safety data provided | Under Review — Penterra and C&H assessed completeness; Broadleaf Scientific Consulting (Dr. Raymond Kapoor) delivered supplemental clinical assessment on Aug. 19, 2024 raising additional questions about data completeness | M. Chu / O. Mackenzie | C&H prepared separate analysis memo dated Aug. 18, 2024 evaluating timeliness and completeness of this notification; notification deemed timely but completeness of underlying data questioned | 2024-09-25
2 | § 5.1(b) | Prompt notice of any government action, order, or proceeding affecting the Company | FDA partial clinical hold imposed on VRD-4187 (IND 154832) | 2024-08-22 | Prompt (interpreted as within 1–2 business days) | 2024-08-23 | Yes — received within 1 business day | Veridian (Dr. Anne-Marie Fontaine / Rachel Stein-Goldberg) via LAC | Penterra (Thomas F. Holbrook); copy to C&H (O. Mackenzie / M. Chu) | FDA imposed partial clinical hold on VRD-4187 pending investigation of CRS-related deaths; hold letter reference IND 154832; new patient enrollment suspended | Complete | M. Chu | Incorporated into C&H's MAE analysis memo dated Aug. 25, 2024 and supplemental MAE analysis dated Sept. 2, 2024 | 2024-09-25
3 | § 5.1(b) | Prompt notice of material changes to clinical trial protocols or regulatory submissions | Veridian implements Protocol v4.0 amendment — mandatory tocilizumab prophylaxis; dose reduction from 1.5 mg/kg to 0.75 mg/kg | 2024-08-28 | Prompt (interpreted as within 1–2 business days; or prior consent may have been required) | 2024-08-29 | Disputed — notification was prompt but Penterra contends prior consent was required under § 5.1(b)(xi), not merely notification | Veridian (Dr. Anne-Marie Fontaine) via LAC (Jonathan Pratt) | Penterra (Natalie Reiner); copy to C&H (M. Chu) | Summary of Protocol v4.0 changes; rationale citing DMC recommendation and FDA clinical hold requirements | Complete as notification; but Penterra's position is that this action required prior consent, not just notification | M. Chu / O. Mackenzie | C&H sent consent request letter to LAC dated Aug. 30, 2024; unresolved at termination. See Covenant Compliance Log Item 15. | 2024-09-30
4 | § 5.4 | No-shop provision — notification of any unsolicited Acquisition Proposal | No event | N/A | Prompt upon receipt | N/A — no Acquisition Proposals reported | N/A | N/A | N/A | No unsolicited Acquisition Proposals received or reported by Veridian during interim period | N/A | D. Okonkwo | No-shop provision (§ 5.4) in effect from signing through termination; includes fiduciary-out for unsolicited Superior Proposals with 4 business days' matching rights for Penterra. No triggers reported. | 2024-09-30
5 | § 5.1(b) | Prompt notice of any material litigation or threatened litigation against the Company | No event | N/A | Prompt upon receipt or knowledge | N/A — no litigation events reported | N/A | N/A | N/A | No material litigation or threatened litigation reported by Veridian during interim period | N/A | D. Okonkwo | Confirmed via periodic inquiries to LAC; no changes from SPA Schedule 3.14 (Litigation) disclosures | 2024-09-25
6 | § 5.1(b) | Prompt notice of any material breach of representations or warranties that would cause closing condition failure | Potential implication from DMC findings and FDA clinical hold — representations re: regulatory compliance (§ 3.15) and absence of MAE (§ 3.8) potentially affected | 2024-08-14 / 2024-08-22 | Prompt (interpreted as within 1–2 business days) | N/A — Veridian did not deliver a separate notification of potential representations breach | Disputed — Penterra contends separate notification of potential representations breach was required | N/A — not delivered | N/A | No separate notification delivered by Veridian regarding potential impact of DMC findings / FDA hold on bring-down of representations | Under Review — Penterra's position is that Veridian should have separately notified of potential breach of §§ 3.8 and 3.15 representations | M. Chu | Relevant to litigation preparation; C&H analysis memo (Sept. 2, 2024) addresses whether DMC notification subsumed this obligation | 2024-09-30
[sheet: Key Events Timeline]
Date | Event | SPA Section Implicated | Action Required / Taken by C&H | Status / Outcome | Responsible Attorney
2024-06-10 | SPA executed by Dr. Anand Rajagopal (Penterra) and Dr. Julian Marek (Veridian); David Ng appointed Stockholder Representative | All | Tracker initiated; begin monitoring interim covenants | Signing complete | M. Chu
2024-06-11 | Compliance tracker initiated by C&H; initial baseline review of Veridian operations | § 5.1 | Set up monitoring framework; establish periodic reporting cadence with LAC | Active | D. Okonkwo
2024-06-12 | R&W insurance policy (No. AIC-RWI-2024-07892) bound with Atlas Indemnity Insurance Co.; $180M limit, $9M SIR, $3,960,000 premium | N/A (ancillary) | Confirmed binding; coordinated with Prescott Whitfield Insurance Brokers (Amanda Chen-Kowalski) | Complete | M. Chu
2024-06-14 | Veridian stockholder written consent delivered — >90% approval (Crestline 28.3%, Boreal 19.7%, Apex 14.1%, founders, and others) | § 7.1 | Confirmed receipt and sufficiency of consents under DGCL § 228 | Closing condition satisfied | D. Okonkwo
2024-06-21 | HSR Act filing submitted by Penterra and Veridian with FTC/DOJ; filing fee of $280,000 paid by Penterra per SPA § 6.3 | § 6.3 / § 7.1(a) | Coordinated filing preparation; confirmed submission | Filing submitted | D. Okonkwo
2024-07-02 | Revised funds flow memorandum circulated reflecting final term loan mechanics (Summit Ridge / Ironclad) | N/A (closing prep) | Updated funds flow: $500M term loan + $400M PPC cash = $900M; $180M to escrow (Fidelis); $2.5M to SH Rep expense fund; $717.5M net to sellers | Draft circulated | M. Chu
2024-07-19 | HSR waiting period expires without second request; antitrust clearance obtained | § 7.1(a) | Confirmed clearance; updated closing conditions checklist | Closing condition satisfied | D. Okonkwo
2024-07-31 | First periodic covenant compliance certification received from Veridian (via LAC); no issues reported | § 5.1 | Reviewed certification; no action items identified | Compliant | D. Okonkwo
2024-08-14 | Marlowe Asset Management-2 DMC interim analysis: DMC recommends enrollment suspension and dose modification; Grade ≥3 CRS 23.4% (treatment) vs. 4.1% (control); 7 treatment deaths (3.6%) vs. 1 control death (0.5%); ORR 31.4% vs. 28.9% (p=0.58) | § 5.1(b); § 7.2(b) (no-MAE condition) | Escalated to O. Mackenzie; began MAE analysis; engaged Broadleaf Scientific for supplemental assessment | Critical event — MAE analysis initiated | M. Chu / O. Mackenzie
2024-08-16 | Penterra receives formal notification from Veridian of DMC findings (2 calendar days after event) | § 5.1(b) | Assessed timeliness — deemed timely; assessed completeness — questions raised | Notification received; completeness under review | M. Chu
2024-08-18 | C&H prepares analysis memo evaluating timeliness and completeness of Veridian's DMC notification | § 5.1(b) | Memo drafted and circulated internally | Internal memo completed | M. Chu
2024-08-19 | Broadleaf Scientific Consulting (Dr. Raymond Kapoor) delivers supplemental clinical assessment to Penterra | N/A (DD advisor) | Reviewed and incorporated into MAE analysis | Assessment received | M. Chu / O. Mackenzie
2024-08-22 | FDA imposes partial clinical hold on VRD-4187 (IND 154832); hold letter received by Veridian | § 5.1(b); § 7.2(a)-(b) | Updated MAE analysis; prepared supplemental memo (dated Sept. 2, 2024) | Critical regulatory event — closing conditions further jeopardized | M. Chu
2024-08-23 | Penterra receives notification from Veridian of FDA partial clinical hold (1 business day after event) | § 5.1(b) | Assessed timeliness — deemed timely; notification assessed as complete | Notification received; deemed timely and complete | M. Chu
2024-08-25 | C&H delivers MAE Analysis Memo to Penterra (Thomas F. Holbrook / Natalie Reiner) | §§ 7.2(a), 7.2(b), 8.1(d) | Memo analyzing whether DMC findings and FDA hold constitute MAE under SPA definition | Memo delivered | O. Mackenzie / M. Chu
2024-08-28 | Veridian implements Protocol v4.0 amendment: mandatory tocilizumab prophylaxis; dose reduction from 1.5 mg/kg to 0.75 mg/kg — without Penterra's prior consent | § 5.1(b)(xi); § 5.1(a) | Flagged as potential covenant non-compliance; C&H prepared consent request letter | Non-compliance flagged; consent request sent Aug. 30 | M. Chu / O. Mackenzie
2024-08-30 | C&H sends consent request letter to LAC (Rebecca Whitmore) re: Protocol v4.0 amendment | § 5.1(b)(xi) | Letter sent requesting information on whether Penterra consent required | Pending response | M. Chu
2024-09-02 | C&H delivers Supplemental MAE Analysis Memo incorporating FDA clinical hold and Protocol v4.0 amendment | §§ 7.2(a), 7.2(b), 8.1(d) | Supplemental memo delivered to Penterra management and board | Memo delivered | O. Mackenzie / M. Chu
2024-09-06 | Penterra sends Deficiency Notice to Veridian alleging material adverse effect and failure of closing conditions under §§ 7.2(a) and 7.2(b) | §§ 7.2(a), 7.2(b), 8.1(d) | C&H drafted and sent Deficiency Notice; copy to LAC | Notice delivered | O. Mackenzie / M. Chu
2024-09-08 | Ticking fee on $500M commitment commences (90 days post-signing); 0.175%/yr on unfunded commitment | N/A (financing) | Noted for cost tracking; ticking fee accruing at ~$2,397/day ($500M × 0.175% ÷ 365) | Active | D. Okonkwo
2024-09-13 | Veridian responds to Deficiency Notice via LAC (Rebecca Whitmore), disputing MAE and demanding closing | §§ 7.2(a), 7.2(b) | C&H prepared analysis of Veridian's response (dated Sept. 16, 2024) | Response received; analysis underway | M. Chu / O. Mackenzie
2024-09-16 | C&H delivers analysis memo responding to Veridian/LAC's Sept. 13 letter | §§ 7.2(a), 7.2(b), 8.1(d) | Memo analyzing Veridian's defenses and reaffirming termination recommendation | Memo delivered to Penterra | O. Mackenzie / M. Chu
2024-09-24 | C&H delivers Board Memorandum recommending termination of SPA to Penterra Board (Margaret Liu Whitfield, Chair) | § 8.1(d) | Memo delivered; board meeting scheduled | Recommendation delivered | O. Mackenzie
2024-09-25 | Pre-Closing Conditions Checklist updated: No-MAE condition (§ 7.2(b)) — NOT SATISFIED; Representations bring-down (§ 7.2(a)) — NOT SATISFIED; HSR clearance — Satisfied; Stockholder consent — Satisfied | §§ 7.1, 7.2, 7.3 | Final pre-termination assessment of all closing conditions | Key conditions not satisfied | M. Chu / D. Okonkwo
2024-09-27 | Penterra Board adopts resolution authorizing termination of SPA under § 8.1(d) | § 8.1(d) | C&H drafted board resolution; confirmed authorization | Board authorized termination | O. Mackenzie
2024-09-30 | Penterra sends Termination Notice to Veridian and David Ng (Stockholder Representative) pursuant to SPA § 8.1(d) | § 8.1(d) | C&H drafted and sent Termination Notice; compliance tracker closed | SPA TERMINATED | O. Mackenzie / M. Chu
[sheet: Compliance Summary]
Category | Total Covenants Tracked | Compliant | Non-Compliant / Disputed | Under Review | N/A | Notes
Affirmative Covenants (§ 5.1(a)) | 4 | 2 | 0 | 2 | 0 | Under Review items relate to preservation of business organization and material relationships following DMC findings and FDA clinical hold
Negative Covenants (§ 5.1(b)) | 16 | 13 | 1 | 2 | 0 | Non-Compliant: Protocol v4.0 amendment implemented without Buyer's prior consent (Item 15); Under Review: related material contract amendment question (Item 10) and potential lien/IP implications
Notification Obligations (§ 5.1(b) notices) | 0 | 0 | 0 | 0 | 0 | Tracked separately on Notification Obligations Log sheet; 6 notification events tracked
No-Shop Provision (§ 5.4) | 1 | 1 | 0 | 0 | 0 | No Acquisition Proposals reported; fiduciary-out not triggered
TOTAL | 21 | 16 | 1 | 4 | 0 | Compliant: 76.2%; Non-Compliant/Disputed: 4.8%; Under Review: 19.0%
[sheet: Open Issues & Flags]
Issue # | Date Identified | SPA Section | Issue Description | Veridian's Position | Penterra's Position | Current Status | Relevance to MAE / Termination Analysis | C&H Lead | Cross-Reference Documents
1 | 2024-08-28 | § 5.1(b)(xi) / § 5.1(a) | Veridian implemented Protocol v4.0 amendment (tocilizumab prophylaxis, dose reduction from 1.5 mg/kg to 0.75 mg/kg) for VRD-4187 without Penterra's prior written consent | Protocol amendment was required by DMC recommendation and FDA partial clinical hold; constitutes ordinary course regulatory compliance; no consent needed | Material modification of lead clinical program required Buyer's prior consent under § 5.1; unilateral action constitutes covenant breach independent of MAE analysis | Unresolved — consent request sent Aug. 30, 2024; no resolution before termination on Sept. 30, 2024 | Supports MAE analysis — protocol modification is evidence of severity of clinical data issues; also potential independent covenant breach claim | O. Mackenzie / M. Chu | Consent Request Letter (Aug. 30, 2024); MAE Analysis Memo (Aug. 25, 2024); Supplemental MAE Analysis (Sept. 2, 2024); Deficiency Notice (Sept. 6, 2024)
2 | 2024-08-16 | § 5.1(b) | Completeness of Veridian's notification regarding Marlowe Asset Management-2 DMC interim analysis findings — whether all underlying safety data (including individual patient CRS grading and death narratives) was provided | Full summary of DMC findings provided promptly; detailed patient-level data is confidential clinical trial data subject to separate data-sharing protocols | Notification was timely but may have been incomplete; Broadleaf Scientific (Dr. Raymond Kapoor) identified gaps in data provided; raises questions about sufficiency under § 5.1(b) | Under Review — superseded by termination; relevant to litigation preparation | Relevant to potential argument that Veridian failed to comply fully with notification obligations, supporting Penterra's termination position | M. Chu | Notification Obligations Memo (Aug. 18, 2024); Broadleaf Supplemental Assessment (Aug. 19, 2024)
3 | 2024-08-22 | § 5.1(a)(iii) | Impact of FDA partial clinical hold (IND 154832) on Veridian's ability to maintain relationships with 42 clinical trial sites and CRO partners | Clinical hold is a regulatory action beyond Veridian's control; Veridian is using commercially reasonable efforts to maintain site relationships and implement protocol amendment | FDA clinical hold fundamentally disrupts Veridian's core business operations and clinical site relationships; evidence of material adverse effect | Under Review — relevant to closing conditions analysis and litigation | Core element of MAE analysis under §§ 7.2(a) and 7.2(b); supports termination under § 8.1(d) | M. Chu / O. Mackenzie | FDA Clinical Hold Impact Memo (Aug. 23, 2024); MAE Analysis Memo (Aug. 25, 2024); Supplemental MAE Analysis (Sept. 2, 2024)
4 | 2024-08-22 | § 5.1(b) / § 7.2(a) | Whether Veridian was required to deliver separate notification that DMC findings and FDA clinical hold may constitute a breach of SPA representations (§§ 3.8 and 3.15) that would cause closing condition failure, independent of the factual notifications already provided | Factual notifications regarding DMC findings and FDA clinical hold encompassed all required notifications; no separate representations-breach notification was required under § 5.1(b) | SPA requires prompt notice of any event that would reasonably be expected to cause failure of closing conditions; a separate notification specifically addressing representations bring-down was required and not provided | Under Review — superseded by termination; relevant to litigation preparation | Supports argument that Veridian's notification compliance was incomplete; may strengthen Penterra's position on termination validity | M. Chu | C&H Supplemental MAE Analysis (Sept. 2, 2024); Notification Obligations Log Item 6